ArticleInternational journal of reproductive biomedicine2025
Association between fibrocystic breast disease and polycystic ovarian syndrome phenotypes: A cross-sectional study.
Article in International journal of reproductive biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders among women of reproductive age and is associated with various hormonal and metabolic complications. Objective: This study aimed to investigate the association between PCOS and fibrocystic breast disease (FBD) and to analyze the prevalence of FBD across different PCOS phenotypes. Materials and Methods: In this cross-sectional study, data of 120 women diagnosed with either FBD or PCOS who referred to Kamali hospital, affiliated with Alborz University of Medical Sciences, Karaj, Iran from March 2024-March 2025 were extracted from their medical records. Participants were divided into 2 groups: PCOS (n = 65) and control (n = 55). The prevalence of FBD was compared between the PCOS and control groups. Furthermore, the distribution of FBD across different PCOS phenotypes (A-D) based on the Rotterdam criteria was analyzed. Hormonal profiles (luteinizing hormone, follicle-stimulating hormone, testosterone, estrogen, progesterone, anti-Müllerian hormone) and metabolic parameters were also compared between the groups. Results: The prevalence of FBD was significantly higher in the PCOS group compared to the control group (58.3% vs. 30%; p = 0.003). The highest prevalence of FBD was observed in phenotype A (81.8%). Logistic regression analysis indicated that having PCOS increased the risk of developing FBD by more than 3 times (odds ratio = 3.12; 95% CI: 1.51-6.45). Levels of luteinizing hormone, follicle-stimulating hormone, and testosterone were significantly elevated in the PCOS group. Conclusion: The findings of this study indicate that PCOS, particularly in phenotypes associated with hyperandrogenism and anovulation, is significantly associated with an increased prevalence of FBD. These results underscore the importance of breast health screening and monitoring in women with PCOS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.